Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsPRNewsWire • Thursday
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PRNewsWire • 10/19/26
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 10/02/26
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast CancerPRNewsWire • 08/13/26
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial ResultsPRNewsWire • 07/28/26
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressPRNewsWire • 05/21/26
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast CancerPRNewsWire • 05/12/26
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/05/26